This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises 2019 revenue and EPS guidance.
Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco
by Zacks Equity Research
Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco
Here's Why You Should Retain PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.
5 Excellent GARP Stocks With Discounted PEG
by Urmimala Biswas
PEG-based investing becomes more rewarding when other relevant parameters are considered.
Cooper Companies' CVI Unit Gets FDA Nod, To Boost Eye Health
by Zacks Equity Research
Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.
Why Cardinal Health (CAH) Could Be a Top Value Stock Pick
by Zacks Equity Research
Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Here's Why You Should Hold on to PerkinElmer Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Here's Why You Should Hold Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Is Deep Value ETF (DVP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVP
Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 16.51% and 0.99%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 7 Earnings Roster: ABC, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Why Earnings Season Could Be Great for Cardinal Health (CAH)
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Hanger (HNGR) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hanger (HNGR) Q3 performance is likely to have benefited from strong demand for Orthotic and Prosthetic services across the board.
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Caremark legacy business is expected to have delivered a solid third quarter, backed by the company's robust execution of its formulary and cost-containment tools.
What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the third quarter.
Can All-Line Growth Boost CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
The newly-incorporated Health Care Benefits business already registers top-line contributions for CVS Health (CVS).
Cardinal Health (CAH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?
by Zacks Equity Research
Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.